An observational study in Alzheimer Disease, sponsored by Maastricht University Medical Center. Completed at 2 sites in Netherlands. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Maastricht University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Alzheimer Disease with a site in Netherlands — 16 open to participants now, 27 under way, 9 of them phase 3. Alzheimer Disease · Netherlands.
Among the 133 studies in Alzheimer Disease with a site in Netherlands, this one is the 11th largest by enrollment of the 14 observational ones that give a count, is one of 12 that started in 2022, is one of 14 observational ones, and was the 109th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →16 of the 133 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Netherlands, Australia, Austria and 14 more countries
Ages 18+
Denali Therapeutics Inc. · Sites in Netherlands, United Kingdom
Ages 18–75
Alnylam Pharmaceuticals · Sites in Netherlands, Canada, Spain and 1 more country
Ages 40–80
Alzheimercentrum Amsterdam · Sites in Netherlands
Ages 55+
Bristol-Myers Squibb · Sites in Netherlands, United States, Argentina and 14 more countries
Ages 60–85
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 45 · Phase 3 47 · Phase 4 1
First in 2000; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is close to the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 241 across the 119 interventional studies, 502 across the 14 observational. Of the 99 that completed or were terminated, 45 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 133 have an industry lead sponsor. The 10 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 6 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Alzheimer Disease with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891716AC Immune SA[18F]ACI-19626 PET in TDP-43 Proteinopathies | 2026-11 |
| NCT07680335Alzheimercentrum AmsterdamThe BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT07328451Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | 2027-02 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 133 studies in Alzheimer Disease with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational longitudinal study is to investigates whether tear fluid is a non-invasive source of biomarkers for Alzheimer's disease. The main aim of the study is to evaluate diagnostic accuracy measures (sensitivity and specificity) of tear and retinal biomarkers to discriminate individuals with and without neurodegeneration.
Tear fluid from participants will be collected non-invasively with Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes. Additionally, standard, ultra-wide field and cross-sectional retinal images will be obtained.
The patients will be selected from the population that visit the memory clinic and are willing to participate in scientific research.
Inclusion Criteria (healthy controls):
Inclusion criteria (patients):
Exclusion Criteria (all subjects):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Includes patients with mild cognitive impairment and dementia
Diagnostic Test: Tear Fluid collection (Schirmer's strip) · Diagnostic Test: Retinal imaging
Includes healthy controls and patients with subjective cognitive decline
Diagnostic Test: Tear Fluid collection (Schirmer's strip) · Diagnostic Test: Retinal imaging
Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
Capability of tear biomarkers to discriminate individuals with neurodegeneration from those without neurodegeneration and assess the change in biomarker levels over time.
Levels of tear biomarkers will be determined from the Schirmer's strips. The biomarker levels will be analysed to see whether they can be discriminate between people with and without neurodegeneration.
Time frame: Sampling done at t= 0, 1 and 2 years.
The difference in tear biomarker level between patients and controls, and between patient groups and how these differences change over time.
Additional analysis to see whether tear biomarkers can also discriminate patients from controls and differences inbetween patient groups.
Time frame: Sampling done at t= 0, 1 and 2 years.
Correlation of biomarker levels in tears, blood and cerebral spinal fluid (CSF).
This analysis will be done to determine the correlation between biomarkers of different body fluids.
Time frame: Baseline measurements (t=0) will be used to determine correlation.
Correlation between tear biomarkers and other ocular imaging biomarkers, as well as assessing the change of this correlation over time.
The correlation between tear biomarkers and ocular imaging biomarkers (e.g. thickness of the retinal nerve fiber layer, retinal vasculature tortuosity) will be analysed.
Time frame: Imaging done at t= 0, 1 and 2 years.
Plan to share: Undecided
Ran from Jun 2022 to primary completion in Jul 2026, 48 months.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's 48 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2025 → Jul 2026 and completion Jul 2025 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →